Although there is a growing interest in using the STAT3 signaling pathway to reduce inflammatory responses in tendinopathies, there are still many issues that need to be further investigated, such as the lack of an accepted standard for the dose or duration of drug intervention in many trials, which is therefore still a long way from being applied in clinical trials. This evidence concerns the gene STAT3 and disease of the tendon.